Company portrait
Insights

HumanOptics develops, manufactures, and sells premium intraocular implantable solutions. Our goal is to create the conditions for restoring the best possible vision to patients to improve their quality of life. We achieve that by offering a broad, highly innovative product portfolio – from standard cataract lenses and premium products to individual custom-made solutions – this enables us to meet the most diverse requirements of surgeons and patients.

Strength in innovation, together with outstanding technical precision (Sub-nano resolution technology), maximum quality awareness, and individual customer orientation are the guiding principles that we as a company are committed to.

We have been manufacturing intraocular lenses (IOLs) for nearly four decades – in fact, we were one of the first in the world to do so. The merger of Dr. Schmidt Intraocularlinsen GmbH (Sankt Augustin) and HumanOptics AG (Erlangen) in 2001 laid the groundwork for our current success. By bundling our expertise, we have managed to establish our presence on a more global scale and today we export around the world. With state-of-the-art manufacturing technologies, sub-nano resolution technology, we have made a name for ourselves as an innovation leader in the field of premium and customized products. Our portfolio includes premium IOLs beyond standard areas.

Thus, we are known for our expertise in the individual production of IOLs with extreme dioptric values. Our goal is to enable patients to achieve optimum visual performance in a targeted and individual way, even in complex and very demanding cases.

An example that illustrates our customer and patient-oriented strength in innovation is the globally unique iris implant CUSTOMFLEX^® ARTIFICIALIRIS.

This iris prosthesis for treating patients with injured or missing irides was awarded breakthrough device status by the FDA (U.S. Food and Drug Administration). “Breakthrough device” recognizes products considered to be groundbreaking. This status was introduced to accelerate market access for new medical products and technologies. In the context of the approval, the FDA is committed to providing rapid market access for the CUSTOMFLEX^® ARTIFICIALIRIS to meet urgent medical needs.

The CUSTOMFLEX^® ARTIFICIALIRIS received FDA approval on May 31, 2018.